Premium
Aspirin does not influence the effect of angiotensin‐converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction
Author(s) -
Hurlen Mette,
Hole Torstein,
Seljeflot Ingebjørg,
Arnesen Harald
Publication year - 2001
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(00)00138-0
Subject(s) - aspirin , medicine , ejection fraction , myocardial infarction , warfarin , cardiology , angiotensin converting enzyme , heart failure , atrial fibrillation , blood pressure
The aim of the present study was to evaluate the possible interaction between chronic aspirin therapy and angiotensin‐converting enzyme inhibitor (ACE‐I) on left ventricular ejection fraction (LVEF) in patients surviving an acute myocardial infarction (AMI). Forty‐two patients with reduced LVEF were recruited from the warfarin aspirin reinfarction study (WARIS‐II), a randomized, open study comparing enteric coated aspirin (160 mg/d), warfarin (INR 2.8–4.2) and the combination of aspirin (75 mg/d) and warfarin (INR 2.0–2.5) on mortality, reinfarction and stroke after AMI. LVEF and relevant biochemical measurements were performed before discharge and after 3 months. The overall LVEF increased during the study period from median 35 to 39% ( P < 0.001). There was no difference between patients on aspirin and warfarin regarding the main end point, LVEF. Furthermore, neither endothelin‐1 nor ANP showed significant differences between the treatment groups. A possible interaction between ACE‐I and aspirin might theoretically lead to reduced levels of renin activity in patients on aspirin, but we did not find any such inter‐group difference. In conclusion, we did not find evidence of interaction between ACE‐I and low‐dose aspirin.